Evidence map›Paper›PMID 40035468›Full record

ArticleImmunology2025

Cytotoxic Signature and IFN-γ Production Dominate CD4

Priscilla Miranda Henriques, Gregório Guilherme Almeida, Inga Rimkute, Luara Isabela Dos Santos, Thomas Liechti, Ana Paula Marino, Isabela Natália Pascoal Campos do Vale, Daniel Vitor Vasconcelos-Santos, Olindo Assis Martins-Filho, Ricardo Tostes Gazzinelli and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Priscilla Miranda HenriquesBiology and Immunology of Infectious and Parasitic Diseases Group, René Rachou Institute, Oswaldo Cruz Foundation-FIOCRUZ, Belo Horizonte, Minas Gerais, Brazil.
Gregório Guilherme AlmeidaBiology and Immunology of Infectious and Parasitic Diseases Group, René Rachou Institute, Oswaldo Cruz Foundation-FIOCRUZ, Belo Horizonte, Minas Gerais, Brazil.
Inga RimkuteVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Luara Isabela Dos SantosBiology and Immunology of Infectious and Parasitic Diseases Group, René Rachou Institute, Oswaldo Cruz Foundation-FIOCRUZ, Belo Horizonte, Minas Gerais, Brazil.
Thomas LiechtiVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Ana Paula MarinoBiology and Immunology of Infectious and Parasitic Diseases Group, René Rachou Institute, Oswaldo Cruz Foundation-FIOCRUZ, Belo Horizonte, Minas Gerais, Brazil.
Isabela Natália Pascoal Campos do ValeBiology and Immunology of Infectious and Parasitic Diseases Group, René Rachou Institute, Oswaldo Cruz Foundation-FIOCRUZ, Belo Horizonte, Minas Gerais, Brazil.
Daniel Vitor Vasconcelos-SantosDepartment of Ophthalmology and Otorhinolaryngology, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Olindo Assis Martins-FilhoIntegrated Research Group in Biomarkers, René Rachou Institute, Oswaldo Cruz Foundation-FIOCRUZ, Belo Horizonte, Minas Gerais, Brazil.
Ricardo Tostes GazzinelliLaboratory of Immunopathology, René Rachou Institute, Oswaldo Cruz Foundation-FIOCRUZ, Belo Horizonte, Minas Gerais, Brazil.
Mario RoedererVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Alan SherImmunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Andréa Teixeira-CarvalhoIntegrated Research Group in Biomarkers, René Rachou Institute, Oswaldo Cruz Foundation-FIOCRUZ, Belo Horizonte, Minas Gerais, Brazil.
Dragana JankovicImmunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Lis Ribeiro do Valle AntonelliBiology and Immunology of Infectious and Parasitic Diseases Group, René Rachou Institute, Oswaldo Cruz Foundation-FIOCRUZ, Belo Horizonte, Minas Gerais, Brazil.ORCID 0000-0002-4969-8812

Funding

Conselho Nacional de Desenvolvimento Científico e TecnológicoCoordenação de Aperfeiçoamento de Pessoal de Nível SuperiorDivision of Intramural Research, National Institute of Allergy and Infectious DiseasesFIOCRUZ-MGFundação de Amparo à Pesquisa do Estado de Minas Gerais APQ02448-18Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-02813-23Instituto Nacional de Ciência e Tecnologia de Vacinas 465293/2014-0Instituto Nacional de Ciência e Tecnologia de Vacinas CBB-APQ-03608-17NIH
6 · The paper itself

Abstract

Toxoplasma gondii is a highly versatile parasite that infects most warm-blooded animals and is a major cause of retinochoroiditis and uveitis in humans. The pathophysiology of these conditions remains poorly understood. Both parasite virulence and host inflammatory response contribute to the development of ocular disease. While CD4

Indexed as

CD4-Positive T-LymphocytesCytotoxicity, ImmunologicInterferon-gammaToxoplasmaToxoplasmosisToxoplasmosis, OcularAdultFemaleHumansMaleMiddle AgedYoung AdultInterferon-gammaCD4+ T cellscytotoxic T cellshuman toxoplasmosistoxoplasma gondii

Identifiers

PMID40035468
PMCPMC12052435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.